December 9th 2024
Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
The Role of BTK Inhibitors in the Evolving CSU Treatment Landscape
December 6th 2024Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors are reshaping the evolving treatment landscape for chronic spontaneous urticaria (CSU) by providing targeted therapeutic options that address underlying mast cell activation.
The Importance of Patient Education and Shared Decision-Making in CSU
December 6th 2024Panelists discuss how patient education and shared decision-making are crucial in selecting appropriate therapies, as they empower patients to understand their treatment options and actively participate in their care.